Evidence map›Paper›PMID 41803553›Full record

ArticleEuropean radiology2026

Breast edema score as a biomarker of tumor aggressiveness and its predictive value for neoadjuvant chemotherapy response.

Mustafa Arda Onar, Elvin Jabbarlı, Ahmet Veysel Polat, Guzin Demirag, Yurdanur Sullu, Ayfer Kamalı Polat

Abstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mustafa Arda OnarDepartment of Radiology, Bartın State Hospital, Bartın, Türkiye. arda_onar@yahoo.com.ORCID http://orcid.org/0000-0003-2756-9857
Elvin JabbarlıDepartment of Radiology, Melhem Beynelxalq Hospital, Baku, Azerbaijan.
Ahmet Veysel PolatDepartment of Radiology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Türkiye.
Guzin DemiragDepartment of Medical Oncology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Türkiye.
Yurdanur SulluDepartment of Pathology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Türkiye.
Ayfer Kamalı PolatDepartment of General Surgery, Ondokuz Mayıs University Faculty of Medicine, Samsun, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate MRI-based breast edema patterns as biomarkers of tumor aggressiveness and their predictive value for pathological response to neoadjuvant chemotherapy (NAC) in invasive breast cancer. MATERIALS AND

methodsThis retrospective study evaluated 235 female patients (mean age, 52 ± 12 years) with biopsy-proven invasive breast cancer who underwent pre-NAC breast MRI. After excluding 19 patients (10 for inadequate image quality, 9 for post-biopsy imaging), 216 patients were analyzed. Breast edema score (BES) was independently assessed by two radiology residents to evaluate interobserver agreement. Subsequently, a breast radiologist reviewed all cases to establish the definitive dataset. The differences in clinicopathological characteristics between the two groups and between different BES were compared.

resultsInterobserver agreement for BES classification was very high (92.6% concordance). Edema presence correlated significantly with larger tumor size (p = 0.001), higher histological grade (p = 0.001), axillary lymph node metastasis (p = 0.015), hormone receptor negativity (p < 0.001), lymphovascular invasion (p = 0.031), and elevated Ki-67 (p = 0.001). Higher BES groups (BES 2-4) showed stronger associations with aggressive features: tumor size (p < 0.001), grade (p = 0.022), hormone receptor negativity (p = 0.001), non-luminal subtypes (p = 0.001), and intratumoral necrosis (p = 0.002). Neither edema nor BES predicted pathological response to NAC (p = 0.999, p = 0.299).

conclusionBES and edema are robust imaging biomarkers of tumor aggressiveness but demonstrate no predictive value for NAC response. MRI-based edema scoring holds clinical relevance for noninvasive tumor phenotyping and risk stratification in breast cancer management. KEY POINTS: Question Can MRI-based breast edema patterns predict tumor aggressiveness and pathological response to neoadjuvant chemotherapy in invasive breast cancer patients, aiding noninvasive risk stratification? Findings BES correlates with aggressive tumor features (larger size, higher grade, hormone negativity; all p < 0.050 but shows no predictive value for NAC response (p = 0.299). Clinical relevance BES serves as a practical imaging biomarker for risk stratification and tumor phenotyping, guiding individualized therapy. However, it shows no utility in predicting NAC response, emphasizing the need for complementary predictive tools in treatment planning.

Indexed as

Breast NeoplasmsEdemaMagnetic Resonance ImagingNeoadjuvant TherapyAdultAgedBiomarkers, TumorChemotherapy, AdjuvantFemaleHumansMiddle AgedNeoplasm InvasivenessPredictive Value of TestsRetrospective StudiesTreatment OutcomeBiomarkers, TumorBreast neoplasmsEdemaMagnetic resonance imagingNeoadjuvant therapy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.